Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
Identifieur interne : 000D43 ( Main/Exploration ); précédent : 000D42; suivant : 000D44Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
Auteurs : P Noel Barrett [États-Unis] ; Sara J. Terpening [États-Unis] ; Doris Snow [États-Unis] ; Ronald R. Cobb [États-Unis] ; Otfried Kistner [États-Unis]Source :
- Expert review of vaccines [ 1744-8395 ] ; 2017.
Descripteurs français
- KwdFr :
- Animaux, Cellules Vero, Facteurs temps, Humains, Maladies transmissibles émergentes (), Maladies transmissibles émergentes (épidémiologie), Maladies virales (), Maladies virales (épidémiologie), Technologie pharmaceutique (), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins antiviraux (isolement et purification), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Vaccins inactivés (isolement et purification).
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins inactivés.
- immunologie : Vaccins antiviraux, Vaccins inactivés.
- isolement et purification : Vaccins antiviraux, Vaccins inactivés.
- épidémiologie : Maladies transmissibles émergentes, Maladies virales.
- Animaux, Cellules Vero, Facteurs temps, Humains, Maladies transmissibles émergentes, Maladies virales, Technologie pharmaceutique.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Communicable Diseases, Emerging (epidemiology), Communicable Diseases, Emerging (prevention & control), Humans, Technology, Pharmaceutical (methods), Time Factors, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology), Vaccines, Inactivated (isolation & purification), Vero Cells, Viral Vaccines (administration & dosage), Viral Vaccines (immunology), Viral Vaccines (isolation & purification), Virus Diseases (epidemiology), Virus Diseases (prevention & control).
- MESH :
- chemical , administration & dosage : Vaccines, Inactivated, Viral Vaccines.
- epidemiology : Communicable Diseases, Emerging, Virus Diseases.
- chemical , immunology : Vaccines, Inactivated, Viral Vaccines.
- chemical , isolation & purification : Vaccines, Inactivated, Viral Vaccines.
- methods : Technology, Pharmaceutical.
- prevention & control : Communicable Diseases, Emerging, Virus Diseases.
- Animals, Chlorocebus aethiops, Humans, Time Factors, Vero Cells.
Abstract
Rapid development and production of vaccines against emerging diseases requires well established, validated, robust technologies to allow industrial scale production and accelerated licensure of products. Areas covered: A versatile Vero cell platform has been developed and utilized to deliver a wide range of candidate and licensed vaccines against emerging viral diseases. This platform builds on the 35 years' experience and safety record with inactivated whole virus vaccines such as polio vaccine. The current platform has been optimized to include a novel double inactivation procedure in order to ensure a highly robust inactivation procedure for novel emerging viruses. The utility of this platform in rapidly developing inactivated whole virus vaccines against pandemic (-like) influenza viruses and other emerging viruses such as West Nile, Chikungunya, Ross River and SARS is reviewed. The potential of the platform for development of vaccines against other emerging viruses such as Zika virus is described. Expert commentary: Use of this platform can substantially accelerate process development and facilitate licensure because of the substantial existing data set available for the cell matrix. However, programs to provide vaccines against emerging diseases must allow alternative clinical development paths to licensure, without the requirement to carry out large scale field efficacy studies.
DOI: 10.1080/14760584.2017.1357471
PubMed: 28724343
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A97
- to stream PubMed, to step Curation: 000A97
- to stream PubMed, to step Checkpoint: 000A44
- to stream Ncbi, to step Merge: 002E31
- to stream Ncbi, to step Curation: 002E31
- to stream Ncbi, to step Checkpoint: 002E31
- to stream Main, to step Merge: 000D45
- to stream Main, to step Curation: 000D43
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.</title><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Terpening, Sara J" sort="Terpening, Sara J" uniqKey="Terpening S" first="Sara J" last="Terpening">Sara J. Terpening</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Snow, Doris" sort="Snow, Doris" uniqKey="Snow D" first="Doris" last="Snow">Doris Snow</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Cobb, Ronald R" sort="Cobb, Ronald R" uniqKey="Cobb R" first="Ronald R" last="Cobb">Ronald R. Cobb</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28724343</idno><idno type="pmid">28724343</idno><idno type="doi">10.1080/14760584.2017.1357471</idno><idno type="wicri:Area/PubMed/Corpus">000A97</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A97</idno><idno type="wicri:Area/PubMed/Curation">000A97</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A97</idno><idno type="wicri:Area/PubMed/Checkpoint">000A44</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A44</idno><idno type="wicri:Area/Ncbi/Merge">002E31</idno><idno type="wicri:Area/Ncbi/Curation">002E31</idno><idno type="wicri:Area/Ncbi/Checkpoint">002E31</idno><idno type="wicri:Area/Main/Merge">000D45</idno><idno type="wicri:Area/Main/Curation">000D43</idno><idno type="wicri:Area/Main/Exploration">000D43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.</title><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Terpening, Sara J" sort="Terpening, Sara J" uniqKey="Terpening S" first="Sara J" last="Terpening">Sara J. Terpening</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Snow, Doris" sort="Snow, Doris" uniqKey="Snow D" first="Doris" last="Snow">Doris Snow</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Cobb, Ronald R" sort="Cobb, Ronald R" uniqKey="Cobb R" first="Ronald R" last="Cobb">Ronald R. Cobb</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name><affiliation wicri:level="2"><nlm:affiliation>a Nanotherapeutics Inc. , Alachua , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Nanotherapeutics Inc. , Alachua , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></analytic><series><title level="j">Expert review of vaccines</title><idno type="eISSN">1744-8395</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Communicable Diseases, Emerging (epidemiology)</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Humans</term><term>Technology, Pharmaceutical (methods)</term><term>Time Factors</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (immunology)</term><term>Vaccines, Inactivated (isolation & purification)</term><term>Vero Cells</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (isolation & purification)</term><term>Virus Diseases (epidemiology)</term><term>Virus Diseases (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Facteurs temps</term><term>Humains</term><term>Maladies transmissibles émergentes ()</term><term>Maladies transmissibles émergentes (épidémiologie)</term><term>Maladies virales ()</term><term>Maladies virales (épidémiologie)</term><term>Technologie pharmaceutique ()</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (isolement et purification)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (immunologie)</term><term>Vaccins inactivés (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Technology, Pharmaceutical</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Maladies transmissibles émergentes</term><term>Maladies virales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Humans</term><term>Time Factors</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Facteurs temps</term><term>Humains</term><term>Maladies transmissibles émergentes</term><term>Maladies virales</term><term>Technologie pharmaceutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rapid development and production of vaccines against emerging diseases requires well established, validated, robust technologies to allow industrial scale production and accelerated licensure of products. Areas covered: A versatile Vero cell platform has been developed and utilized to deliver a wide range of candidate and licensed vaccines against emerging viral diseases. This platform builds on the 35 years' experience and safety record with inactivated whole virus vaccines such as polio vaccine. The current platform has been optimized to include a novel double inactivation procedure in order to ensure a highly robust inactivation procedure for novel emerging viruses. The utility of this platform in rapidly developing inactivated whole virus vaccines against pandemic (-like) influenza viruses and other emerging viruses such as West Nile, Chikungunya, Ross River and SARS is reviewed. The potential of the platform for development of vaccines against other emerging viruses such as Zika virus is described. Expert commentary: Use of this platform can substantially accelerate process development and facilitate licensure because of the substantial existing data set available for the cell matrix. However, programs to provide vaccines against emerging diseases must allow alternative clinical development paths to licensure, without the requirement to carry out large scale field efficacy studies.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></region><name sortKey="Cobb, Ronald R" sort="Cobb, Ronald R" uniqKey="Cobb R" first="Ronald R" last="Cobb">Ronald R. Cobb</name><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name><name sortKey="Snow, Doris" sort="Snow, Doris" uniqKey="Snow D" first="Doris" last="Snow">Doris Snow</name><name sortKey="Terpening, Sara J" sort="Terpening, Sara J" uniqKey="Terpening S" first="Sara J" last="Terpening">Sara J. Terpening</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28724343
|texte= Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28724343" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |